Skip to main content

Table 2 Characteristics of studies and patients included in the PFS and OS meta-analysis

From: The characteristics of androgen receptor splice variant 7 in the treatment of hormonal sensitive prostate cancer: a systematic review and meta-analysis

Study Year Country Study design AR-V7 detection assay Patients characteristics
Treatment Patients (n) Age (range) Gleason score (%) Tumor stage at diagnosis (%) Baseline PSA (ng/ml) median (range) Follow-up time (month) Median (range)
Li H [14] 2018 China Retrospective Immunohistochemistry First-line ADT 168 71 (53–96) ≤ 7 (35.7%) ≥ 8 (64.3%) T1/T2 (9.5%) T3/T4 (67.9%) 118.78 (2.61–4003.40) 36 (IQR22–48)
Saylor [22] 2017 USA Retrospective RNA ISH First-line ADT 22
Qu Y [15] 2015 China Retrospective IHC First-line ADT 104 70 (43–84) ≤ 7 (44.2%) ≥ 8 (55.8%) 122.5 (3.0–6006.2) 25 (2–132)
Guo Z [5] 2009 USA Retrospective IHC Radical prostatectomy 224 6–10
  1. IQR inter quartile range, SD standard deviation, AR-V7 androgen receptor splice variant 7, CTC circulating tumor cell, PSA prostate specific antigen, ADT androgen deprivation therapy, ARS inhibitor androgen receptor signal inhibitor, LHRH luteinizing hormone releasing hormone